WHO ICTRP trial
A phase 3 study of TAS-115 in patients with osteosarcoma
JPRN-jRCT2080225239 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2080225239 |
|---|---|
| Public title | A phase 3 study of TAS-115 in patients with osteosarcoma |
| Scientific title | A Phase III, double blind, randomized, placebo controlled study to evaluate the efficacy of TAS-115 in patients with osteosarcoma treated standard chemotherapy |
| Primary sponsor | Taiho Pharmaceutical Co., Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Japan |
| Conditions | Osteosarcoma |
| Interventions | investigational material(s) Generic name etc : pamufetinib INN of investigational material : pamufetinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : TAS-115 will be… |
| Registration date | Jun 22, 2020 |
| Target size | 77 |
| Secondary IDs | JapicCTI-205335 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: